Fisher & Paykel Healthcare says the second half of the financial year is in line with the first, with a decline in the number of respiratory interventions associated with Omicron as well as a mild flu season in the Northern Hemisphere.
The Vitera device for sleep apnea made by Fisher and Paykel. (Photo file)
Photo: Delivered / Fisher and Paykel Health Care
At current dollar rates, the respiratory health insurance company expects full-year operating income, which ended in March, to be in the range of $ 1.675 billion to $ 1.70b, compared to $ 1.97b last year.
“In our Homecare product group, the growth in sales of our OSA (obstructive sleep apnea) masks is currently above our first half growth rate despite supply constraints of treatment hardware on the market,” said chief executive Lewis Gradon.
“Freight rates remain high and for fiscal year 2022 are expected to affect our long-term gross margin target of 65 percent by about 250 basis points.”
Gradon said the company is well placed to respond to Covid-19.
“No matter how the covid-19 effects develop in the short term, we are confident that our business is well placed to contribute to a positive change in clinical practice and to improve outcomes for respiratory patients in general over the long term,” he said.
The company plans to release its full-year result on May 25th.
Add Comment